A JAMA report released suggested a high intake of supplemental calcium is associated with an increased risk of cardiovascular disease death in men was criticized by several dietary supplement agencies for being inconclusive.
A study published Monday online by JAMA may skew the conversation over multivitamin use negative, despite the fact that study authors maintain the study cannot be generalized across the general population given the study's subjects — namely, practicing physicians.
A drug made by Bristol-Myers Squibb and AstraZeneca improved several measures of blood-sugar control in Type 2 diabetes patients at high risk of cardiovascular disease, according to results of a late-stage clinical trial announced Monday.
While headlines in the past two weeks warned consumers that calcium supplementation could increase the risk of cardiovascular disease, authors of the study that prompted those headlines — published last month in the peer-reviewed journal Heart — identified four significant confounding factors in the design of the study.
Recognizing that cardiovascular disease affects about 80 million people in the United States and is the No. 1 killer of Americans, CVS/pharmacy announced on Thursday that it is providing several free services, educational information and special product offers during February's American Heart Month.
A large European study released Tuesday found that daily aspirin use is linked to an increased risk of age-related macular degeneration, a disease that can damage the central vision that is essential for reading and driving.
The National Association of Chain Drug Stores has praised a review article published in this week’s Archives of Internal Medicine, which stated that community pharmacists figure prominently in the successful management of cardiovascular disease risk factors in outpatients, such as reductions in blood pressure and cholesterol.
A special group of patients who participated in a trial of a heart disease drug made by Daiichi Sankyo and Eli Lilly showed fewer heart attacks, strokes and deaths related to cardiovascular disease than patients taking a competing drug, according to an analysis of study results.